Posted by Michael Wonder on 25 Sep 2025
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
25 September 2025 - Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline.
Eli Lilly announced today that the European Commission has granted marketing authorisation for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease, in adults with mild cognitive impairment as well as those with mild dementia stages of Alzheimer's disease with confirmed amyloid pathology who are apolipoprotein E heterozygotes or non-carriers.
